While 18F-MK-6240 is a validated marker for tau pathology in AD, it is also characterized by off-target binding to neuromelanin and melanin-containing cells and weak but detectable binding to hemorrhagic tissue in postmortem analyses, but not to vascular Aβ in blood vessel walls [8,9]. The gene discussed is MAPT; the disease is Alzheimer disease.